首页 > 最新文献

Medical Decision Making最新文献

英文 中文
Markov Cohort State-Transition Model: A Multinomial Distribution Representation. 马尔可夫队列状态转移模型:一种多项分布表示。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221112420
Rowan Iskandar, Cassandra Berns

Highlights: A Markov model simulates the average experience of a cohort of patients.Monte Carlo simulation, the standard approach for estimating the variance, is computationally expensive.A multinomial distribution provides an exact representation of a Markov model.Using the known formulas of a multinomial distribution, the mean and variance of a Markov model can be readily calculated.

一个马尔可夫模型模拟了一群病人的平均经历。蒙特卡罗模拟是估计方差的标准方法,计算成本很高。多项分布提供了马尔可夫模型的精确表示。利用已知的多项分布公式,可以很容易地计算出马尔可夫模型的均值和方差。
{"title":"Markov Cohort State-Transition Model: A Multinomial Distribution Representation.","authors":"Rowan Iskandar,&nbsp;Cassandra Berns","doi":"10.1177/0272989X221112420","DOIUrl":"https://doi.org/10.1177/0272989X221112420","url":null,"abstract":"<p><strong>Highlights: </strong>A Markov model simulates the average experience of a cohort of patients.Monte Carlo simulation, the standard approach for estimating the variance, is computationally expensive.A multinomial distribution provides an exact representation of a Markov model.Using the known formulas of a multinomial distribution, the mean and variance of a Markov model can be readily calculated.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"139-142"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10347959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analytical Frameworks and Outcome Measures in Economic Evaluations of Digital Health Interventions: A Methodological Systematic Review. 数字健康干预经济评估中的分析框架和结果测量:方法系统回顾。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221132741
Valerio Benedetto, Luís Filipe, Catherine Harris, Joseph Spencer, Carmel Hickson, Andrew Clegg
<p><strong>Background: </strong>Digital health interventions (DHIs) can improve the provision of health care services. To fully account for their effects in economic evaluations, traditional methods based on measuring health-related quality of life may not be appropriate, as nonhealth and process outcomes are likely to be relevant too.</p><p><strong>Purpose: </strong>This systematic review identifies, assesses, and synthesizes the arguments on the analytical frameworks and outcome measures used in the economic evaluations of DHIs. The results informed recommendations for future economic evaluations.</p><p><strong>Data sources: </strong>We ran searches on multiple databases, complemented by gray literature and backward and forward citation searches.</p><p><strong>Study selection: </strong>We included records containing theoretical and empirical arguments associated with the use of analytical frameworks and outcome measures for economic evaluations of DHIs. Following title/abstract and full-text screening, our final analysis included 15 studies.</p><p><strong>Data extraction: </strong>The arguments we extracted related to analytical frameworks (14 studies), generic outcome measures (5 studies), techniques used to elicit utility values (3 studies), and disease-specific outcome measures and instruments to collect health states data (both from 2 studies).</p><p><strong>Data synthesis: </strong>Rather than assessing the quality of the studies, we critically assessed and synthesized the extracted arguments. Building on this synthesis, we developed a 3-stage set of recommendations in which we encourage the use of impact matrices and analyses of equity impacts to integrate traditional economic evaluation methods.</p><p><strong>Limitations: </strong>Our review and recommendations explored but not fully covered other potentially important aspects of economic evaluations that were outside our scope.</p><p><strong>Conclusions: </strong>This is the first systematic review that summarizes the arguments on how the effects of DHIs could be measured in economic evaluations. Our recommendations will help design future economic evaluations.</p><p><strong>Highlights: </strong>Using traditional outcome measures based on health-related quality of life (such as the quality-adjusted life-year) may not be appropriate in economic evaluations of digital health interventions, which are likely to trigger nonhealth and process outcomes.This is the first systematic review to investigate how the effects of digital health interventions could be measured in economic evaluations.We extracted and synthesized different arguments from the literature, outlining advantages and disadvantages associated with different methods used to measure the effects of digital health interventions.We propose a methodological set of recommendations in which 1) we suggest that researchers consider the use of impact matrices and cost-consequence analysis, 2) we discuss the suitability of analytical frame
背景:数字卫生干预(DHIs)可以改善卫生保健服务的提供。为了在经济评价中充分考虑其影响,以衡量与健康有关的生活质量为基础的传统方法可能不合适,因为非健康和过程结果也可能相关。目的:本系统综述识别、评估和综合了在DHIs经济评估中使用的分析框架和结果测量的论点。结果为今后的经济评价提供了建议。数据来源:我们在多个数据库中进行了搜索,并辅以灰色文献和前后引文搜索。研究选择:我们纳入了包含与使用分析框架和结果测量方法进行DHIs经济评估相关的理论和实证论点的记录。经过标题/摘要和全文筛选,我们的最终分析包括15项研究。数据提取:我们提取的论点与分析框架(14项研究)、通用结果测量(5项研究)、用于得出效用值的技术(3项研究)以及特定疾病的结果测量和收集健康状态数据的工具(均来自2项研究)有关。数据综合:我们不是评估研究的质量,而是批判性地评估和综合提取的论点。在此综合基础上,我们制定了一套分为三个阶段的建议,其中我们鼓励使用影响矩阵和公平影响分析来整合传统的经济评估方法。局限性:我们的综述和建议探讨了但未完全涵盖超出我们范围的经济评估的其他潜在重要方面。结论:这是第一个系统综述,总结了如何在经济评估中衡量DHIs的影响的论点。我们的建议将有助于设计未来的经济评估。重点:在数字卫生干预措施的经济评估中,使用基于健康相关生活质量的传统结果度量(如质量调整生命年)可能不合适,因为这可能引发非健康和过程结果。这是研究如何在经济评估中衡量数字卫生干预措施的影响的第一个系统综述。我们从文献中提取并综合了不同的论点,概述了用于衡量数字健康干预效果的不同方法的优缺点。我们提出了一套方法建议,其中1)我们建议研究人员考虑使用影响矩阵和成本后果分析,2)我们讨论了经济评估中可用的分析框架和结果测量的适用性,3)我们强调了分析公平影响的必要性。
{"title":"Analytical Frameworks and Outcome Measures in Economic Evaluations of Digital Health Interventions: A Methodological Systematic Review.","authors":"Valerio Benedetto,&nbsp;Luís Filipe,&nbsp;Catherine Harris,&nbsp;Joseph Spencer,&nbsp;Carmel Hickson,&nbsp;Andrew Clegg","doi":"10.1177/0272989X221132741","DOIUrl":"https://doi.org/10.1177/0272989X221132741","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Digital health interventions (DHIs) can improve the provision of health care services. To fully account for their effects in economic evaluations, traditional methods based on measuring health-related quality of life may not be appropriate, as nonhealth and process outcomes are likely to be relevant too.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;This systematic review identifies, assesses, and synthesizes the arguments on the analytical frameworks and outcome measures used in the economic evaluations of DHIs. The results informed recommendations for future economic evaluations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data sources: &lt;/strong&gt;We ran searches on multiple databases, complemented by gray literature and backward and forward citation searches.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study selection: &lt;/strong&gt;We included records containing theoretical and empirical arguments associated with the use of analytical frameworks and outcome measures for economic evaluations of DHIs. Following title/abstract and full-text screening, our final analysis included 15 studies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data extraction: &lt;/strong&gt;The arguments we extracted related to analytical frameworks (14 studies), generic outcome measures (5 studies), techniques used to elicit utility values (3 studies), and disease-specific outcome measures and instruments to collect health states data (both from 2 studies).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data synthesis: &lt;/strong&gt;Rather than assessing the quality of the studies, we critically assessed and synthesized the extracted arguments. Building on this synthesis, we developed a 3-stage set of recommendations in which we encourage the use of impact matrices and analyses of equity impacts to integrate traditional economic evaluation methods.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;Our review and recommendations explored but not fully covered other potentially important aspects of economic evaluations that were outside our scope.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This is the first systematic review that summarizes the arguments on how the effects of DHIs could be measured in economic evaluations. Our recommendations will help design future economic evaluations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Using traditional outcome measures based on health-related quality of life (such as the quality-adjusted life-year) may not be appropriate in economic evaluations of digital health interventions, which are likely to trigger nonhealth and process outcomes.This is the first systematic review to investigate how the effects of digital health interventions could be measured in economic evaluations.We extracted and synthesized different arguments from the literature, outlining advantages and disadvantages associated with different methods used to measure the effects of digital health interventions.We propose a methodological set of recommendations in which 1) we suggest that researchers consider the use of impact matrices and cost-consequence analysis, 2) we discuss the suitability of analytical frame","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"125-138"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10350862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Utilizing Clinical Trial Data to Assess Timing of Surgical Treatment for Emphysema Patients. 利用临床试验数据评估肺气肿患者的手术治疗时机。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221132256
Maryam Alimohammadi, W Art Chaovalitwongse, Hubert J Vesselle, Shengfan Zhang

Background: Lung volume reduction surgery (LVRS) and medical therapy are 2 available treatment options in dealing with severe emphysema, which is a chronic lung disease. However, or there are currently limited guidelines on the timing of LVRS for patients with different characteristics.

Objective: The objective of this study is to assess the timing of receiving LVRS in terms of patient outcomes, taking into consideration a patient's characteristics.

Methods: A finite-horizon Markov decision process model for patients with severe emphysema was developed to determine the short-term (5 y) and long-term timing of emphysema treatment. Maximizing the expected life expectancy, expected quality-adjusted life-years, and total expected cost of each treatment option were applied as the objective functions of the model. To estimate parameters in the model, the data provided by the National Emphysema Treatment Trial were used.

Results: The results indicate that the treatment timing strategy for patients with upper-lobe predominant emphysema is to receive LVRS regardless of their specific characteristics. However, for patients with non-upper-lobe-predominant emphysema, the optimal strategy depends on the age, maximum workload level, and forced expiratory volume in 1 second level.

Conclusion: This study demonstrates the utilization of clinical trial data to gain insights into the timing of surgical treatment for patients with emphysema, considering patient age, observable health condition, and location of emphysema.

Highlights: Both short-term and long-term Markov decision process models were developed to assess the timing of receiving lung volume reduction surgery in patients with severe emphysema.How clinical trial data can be used to estimate the parameters and obtain short-term results from the Markov decision process model is demonstrated.The results provide insights into the timing of receiving lung volume reduction surgery as a function of a patient's characteristics, including age, emphysema location, maximum workload, and forced expiratory volume in 1 second level.

背景:肺减容手术(LVRS)和药物治疗是治疗严重肺气肿(一种慢性肺部疾病)的两种可行的治疗方法。然而,对于不同特征的患者,目前关于LVRS时机的指南有限。目的:本研究的目的是根据患者的特点,评估接受LVRS的时机。方法:建立严重肺气肿患者的有限视界马尔可夫决策过程模型,确定肺气肿的短期(5 y)和长期治疗时机。每个治疗方案的预期寿命、预期质量调整寿命年和总预期成本以最大化为模型的目标函数。为了估计模型中的参数,使用了国家肺气肿治疗试验提供的数据。结果:结果表明,对于上肺叶显性肺气肿患者,无论其具体特征如何,均应采用LVRS治疗。然而,对于非上叶为主的肺气肿患者,最佳策略取决于年龄、最大负荷水平和1秒内的用力呼气量。结论:本研究展示了利用临床试验数据来深入了解肺气肿患者的手术治疗时机,考虑患者的年龄、可观察到的健康状况和肺气肿的位置。重点:开发了短期和长期马尔可夫决策过程模型来评估严重肺气肿患者接受肺减容手术的时机。演示了如何使用临床试验数据来估计参数并从马尔可夫决策过程模型中获得短期结果。结果提供了接受肺减容手术的时机作为患者特征的函数的见解,包括年龄,肺气肿位置,最大工作量和1秒内的用力呼气量。
{"title":"Utilizing Clinical Trial Data to Assess Timing of Surgical Treatment for Emphysema Patients.","authors":"Maryam Alimohammadi,&nbsp;W Art Chaovalitwongse,&nbsp;Hubert J Vesselle,&nbsp;Shengfan Zhang","doi":"10.1177/0272989X221132256","DOIUrl":"https://doi.org/10.1177/0272989X221132256","url":null,"abstract":"<p><strong>Background: </strong>Lung volume reduction surgery (LVRS) and medical therapy are 2 available treatment options in dealing with severe emphysema, which is a chronic lung disease. However, or there are currently limited guidelines on the timing of LVRS for patients with different characteristics.</p><p><strong>Objective: </strong>The objective of this study is to assess the timing of receiving LVRS in terms of patient outcomes, taking into consideration a patient's characteristics.</p><p><strong>Methods: </strong>A finite-horizon Markov decision process model for patients with severe emphysema was developed to determine the short-term (5 y) and long-term timing of emphysema treatment. Maximizing the expected life expectancy, expected quality-adjusted life-years, and total expected cost of each treatment option were applied as the objective functions of the model. To estimate parameters in the model, the data provided by the National Emphysema Treatment Trial were used.</p><p><strong>Results: </strong>The results indicate that the treatment timing strategy for patients with upper-lobe predominant emphysema is to receive LVRS regardless of their specific characteristics. However, for patients with non-upper-lobe-predominant emphysema, the optimal strategy depends on the age, maximum workload level, and forced expiratory volume in 1 second level.</p><p><strong>Conclusion: </strong>This study demonstrates the utilization of clinical trial data to gain insights into the timing of surgical treatment for patients with emphysema, considering patient age, observable health condition, and location of emphysema.</p><p><strong>Highlights: </strong>Both short-term and long-term Markov decision process models were developed to assess the timing of receiving lung volume reduction surgery in patients with severe emphysema.How clinical trial data can be used to estimate the parameters and obtain short-term results from the Markov decision process model is demonstrated.The results provide insights into the timing of receiving lung volume reduction surgery as a function of a patient's characteristics, including age, emphysema location, maximum workload, and forced expiratory volume in 1 second level.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"110-124"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10357691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness and Value-of-Information Analysis Using Machine Learning-Based Metamodeling: A Case of Hepatitis C Treatment. 基于机器学习的元模型的成本效益和信息价值分析:一个丙型肝炎治疗案例。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221125418
John Austin McCandlish, Turgay Ayer, Jagpreet Chhatwal

Background: Metamodels can address some of the limitations of complex simulation models by formulating a mathematical relationship between input parameters and simulation model outcomes. Our objective was to develop and compare the performance of a machine learning (ML)-based metamodel against a conventional metamodeling approach in replicating the findings of a complex simulation model.

Methods: We constructed 3 ML-based metamodels using random forest, support vector regression, and artificial neural networks and a linear regression-based metamodel from a previously validated microsimulation model of the natural history hepatitis C virus (HCV) consisting of 40 input parameters. Outcomes of interest included societal costs and quality-adjusted life-years (QALYs), the incremental cost-effectiveness (ICER) of HCV treatment versus no treatment, cost-effectiveness analysis curve (CEAC), and expected value of perfect information (EVPI). We evaluated metamodel performance using root mean squared error (RMSE) and Pearson's R2 on the normalized data.

Results: The R2 values for the linear regression metamodel for QALYs without treatment, QALYs with treatment, societal cost without treatment, societal cost with treatment, and ICER were 0.92, 0.98, 0.85, 0.92, and 0.60, respectively. The corresponding R2 values for our ML-based metamodels were 0.96, 0.97, 0.90, 0.95, and 0.49 for support vector regression; 0.99, 0.83, 0.99, 0.99, and 0.82 for artificial neural network; and 0.99, 0.99, 0.99, 0.99, and 0.98 for random forest. Similar trends were observed for RMSE. The CEAC and EVPI curves produced by the random forest metamodel matched the results of the simulation output more closely than the linear regression metamodel.

Conclusions: ML-based metamodels generally outperformed traditional linear regression metamodels at replicating results from complex simulation models, with random forest metamodels performing best.

Highlights: Decision-analytic models are frequently used by policy makers and other stakeholders to assess the impact of new medical technologies and interventions. However, complex models can impose limitations on conducting probabilistic sensitivity analysis and value-of-information analysis, and may not be suitable for developing online decision-support tools.Metamodels, which accurately formulate a mathematical relationship between input parameters and model outcomes, can replicate complex simulation models and address the above limitation.The machine learning-based random forest model can outperform linear regression in replicating the findings of a complex simulation model. Such a metamodel can be used for conducting cost-effectiveness and value-of-information analyses or developing online decision support tools.

背景:元模型可以通过在输入参数和仿真模型结果之间建立数学关系来解决复杂仿真模型的一些局限性。我们的目标是在复制复杂仿真模型的结果时,开发并比较基于机器学习(ML)的元模型与传统元建模方法的性能。方法:我们使用随机森林、支持向量回归和人工神经网络构建了3个基于ml的元模型,以及一个基于线性回归的元模型,该元模型来自先前验证过的由40个输入参数组成的丙型肝炎病毒(HCV)自然史微观模拟模型。关注的结局包括社会成本和质量调整生命年(QALYs)、HCV治疗与不治疗的增量成本-效果(ICER)、成本-效果分析曲线(CEAC)和完美信息期望值(EVPI)。我们使用归一化数据的均方根误差(RMSE)和Pearson’s R2来评估元模型的性能。结果:未治疗的QALYs、治疗后的QALYs、未治疗的社会成本、治疗后的社会成本、ICER的线性回归元模型R2分别为0.92、0.98、0.85、0.92、0.60。基于ml的元模型对应的R2值分别为0.96、0.97、0.90、0.95和0.49;人工神经网络为0.99、0.83、0.99、0.99、0.82;随机森林是0.99,0.99,0.99,0.99和0.98。均方根误差也有类似的趋势。随机森林元模型生成的CEAC和EVPI曲线比线性回归元模型更接近模拟输出的结果。结论:基于ml的元模型在复制复杂模拟模型的结果方面普遍优于传统的线性回归元模型,其中随机森林元模型表现最好。重点:决策分析模型经常被决策者和其他利益相关者用来评估新的医疗技术和干预措施的影响。然而,复杂的模型可能会对概率敏感性分析和信息价值分析施加限制,并且可能不适合开发在线决策支持工具。元模型准确地建立了输入参数与模型结果之间的数学关系,可以复制复杂的仿真模型,解决了上述限制。基于机器学习的随机森林模型在复制复杂模拟模型的结果方面优于线性回归。这种元模型可用于进行成本效益和信息价值分析或开发在线决策支持工具。
{"title":"Cost-Effectiveness and Value-of-Information Analysis Using Machine Learning-Based Metamodeling: A Case of Hepatitis C Treatment.","authors":"John Austin McCandlish,&nbsp;Turgay Ayer,&nbsp;Jagpreet Chhatwal","doi":"10.1177/0272989X221125418","DOIUrl":"https://doi.org/10.1177/0272989X221125418","url":null,"abstract":"<p><strong>Background: </strong>Metamodels can address some of the limitations of complex simulation models by formulating a mathematical relationship between input parameters and simulation model outcomes. Our objective was to develop and compare the performance of a machine learning (ML)-based metamodel against a conventional metamodeling approach in replicating the findings of a complex simulation model.</p><p><strong>Methods: </strong>We constructed 3 ML-based metamodels using random forest, support vector regression, and artificial neural networks and a linear regression-based metamodel from a previously validated microsimulation model of the natural history hepatitis C virus (HCV) consisting of 40 input parameters. Outcomes of interest included societal costs and quality-adjusted life-years (QALYs), the incremental cost-effectiveness (ICER) of HCV treatment versus no treatment, cost-effectiveness analysis curve (CEAC), and expected value of perfect information (EVPI). We evaluated metamodel performance using root mean squared error (RMSE) and Pearson's <i>R</i><sup>2</sup> on the normalized data.</p><p><strong>Results: </strong>The <i>R</i><sup>2</sup> values for the linear regression metamodel for QALYs without treatment, QALYs with treatment, societal cost without treatment, societal cost with treatment, and ICER were 0.92, 0.98, 0.85, 0.92, and 0.60, respectively. The corresponding <i>R</i><sup>2</sup> values for our ML-based metamodels were 0.96, 0.97, 0.90, 0.95, and 0.49 for support vector regression; 0.99, 0.83, 0.99, 0.99, and 0.82 for artificial neural network; and 0.99, 0.99, 0.99, 0.99, and 0.98 for random forest. Similar trends were observed for RMSE. The CEAC and EVPI curves produced by the random forest metamodel matched the results of the simulation output more closely than the linear regression metamodel.</p><p><strong>Conclusions: </strong>ML-based metamodels generally outperformed traditional linear regression metamodels at replicating results from complex simulation models, with random forest metamodels performing best.</p><p><strong>Highlights: </strong>Decision-analytic models are frequently used by policy makers and other stakeholders to assess the impact of new medical technologies and interventions. However, complex models can impose limitations on conducting probabilistic sensitivity analysis and value-of-information analysis, and may not be suitable for developing online decision-support tools.Metamodels, which accurately formulate a mathematical relationship between input parameters and model outcomes, can replicate complex simulation models and address the above limitation.The machine learning-based random forest model can outperform linear regression in replicating the findings of a complex simulation model. Such a metamodel can be used for conducting cost-effectiveness and value-of-information analyses or developing online decision support tools.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"68-77"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10410398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. 在两项延长随访的晚期NSCLC Nivolumab试验中,使用先进的灵活建模方法从早期随访数据推断生存期。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221132257
M A Chaudhary, M Edmondson-Jones, G Baio, E Mackay, J R Penrod, D J Sharpe, G Yates, S Rafiq, K Johannesen, M K Siddiqui, J Vanderpuye-Orgle, A Briggs
<p><strong>Objectives: </strong>Immuno-oncology (IO) therapies are often associated with delayed responses that are deep and durable, manifesting as long-term survival benefits in patients with metastatic cancer. Complex hazard functions arising from IO treatments may limit the accuracy of extrapolations from standard parametric models (SPMs). We evaluated the ability of flexible parametric models (FPMs) to improve survival extrapolations using data from 2 trials involving patients with non-small-cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>Our analyses used consecutive database locks (DBLs) at 2-, 3-, and 5-y minimum follow-up from trials evaluating nivolumab versus docetaxel in patients with pretreated metastatic squamous (CheckMate-017) and nonsquamous (CheckMate-057) NSCLC. For each DBL, SPMs, as well as 3 FPMs-landmark response models (LRMs), mixture cure models (MCMs), and Bayesian multiparameter evidence synthesis (B-MPES)-were estimated on nivolumab overall survival (OS). The performance of each parametric model was assessed by comparing milestone restricted mean survival times (RMSTs) and survival probabilities with results obtained from externally validated SPMs.</p><p><strong>Results: </strong>For the 2- and 3-y DBLs of both trials, all models tended to underestimate 5-y OS. Predictions from nonvalidated SPMs fitted to the 2-y DBLs were highly unreliable, whereas extrapolations from FPMs were much more consistent between models fitted to successive DBLs. For CheckMate-017, in which an apparent survival plateau emerges in the 3-y DBL, MCMs fitted to this DBL estimated 5-y OS most accurately (11.6% v. 12.3% observed), and long-term predictions were similar to those from the 5-y validated SPM (20-y RMST: 30.2 v. 30.5 mo). For CheckMate-057, where there is no clear evidence of a survival plateau in the early DBLs, only B-MPES was able to accurately predict 5-y OS (14.1% v. 14.0% observed [3-y DBL]).</p><p><strong>Conclusions: </strong>We demonstrate that the use of FPMs for modeling OS in NSCLC patients from early follow-up data can yield accurate estimates for RMST observed with longer follow-up and provide similar long-term extrapolations to externally validated SPMs based on later data cuts. B-MPES generated reasonable predictions even when fitted to the 2-y DBLs of the studies, whereas MCMs were more reliant on longer-term data to estimate a plateau and therefore performed better from 3 y. Generally, LRM extrapolations were less reliable than those from alternative FPMs and validated SPMs but remained superior to nonvalidated SPMs. Our work demonstrates the potential benefits of using advanced parametric models that incorporate external data sources, such as B-MPES and MCMs, to allow for accurate evaluation of treatment clinical and cost-effectiveness from trial data with limited follow-up.</p><p><strong>Highlights: </strong>Flexible advanced parametric modeling methods can provide improved survival extrapolations for immu
目的:免疫肿瘤学(IO)治疗通常与深度和持久的延迟反应相关,表现为转移性癌症患者的长期生存益处。IO处理产生的复杂危险函数可能会限制标准参数模型(SPMs)外推的准确性。我们利用两项涉及非小细胞肺癌(NSCLC)患者的试验数据,评估了灵活参数模型(FPMs)改善生存推断的能力。方法:我们的分析使用连续数据库锁定(dbl),在2年、3年和5年的最短随访时间,从试验中评估纳武单抗与多西他赛在预处理转移性鳞状(CheckMate-017)和非鳞状(CheckMate-057)非小细胞肺癌患者中的疗效。对于每个DBL, SPMs以及3个fpm -标志性反应模型(lrm),混合治愈模型(MCMs)和贝叶斯多参数证据合成(B-MPES)-对纳沃单抗总生存期(OS)进行估计。通过比较里程碑限制平均生存时间(RMSTs)和生存概率与外部验证SPMs获得的结果来评估每个参数模型的性能。结果:对于两项试验的2年和3年DBLs,所有模型都倾向于低估5年OS。未经验证的SPMs对2年DBLs的预测是高度不可靠的,而FPMs的外推在连续DBLs的模型之间更为一致。对于CheckMate-017,在3年的DBL中出现了明显的生存平台,适合该DBL的mcm最准确地估计了5年的OS (11.6% vs 12.3%观察到),并且长期预测与5年验证的SPM相似(20年RMST: 30.2 vs 30.5个月)。对于CheckMate-057,在早期DBL中没有明确的生存平台证据,只有B-MPES能够准确预测5年生存率(14.1% vs . 14.0%观察[3年DBL])。结论:我们证明,使用FPMs对NSCLC患者的OS进行建模,可以从早期随访数据中得出更长的随访期间观察到的RMST的准确估计,并为基于后期数据切割的外部验证的SPMs提供类似的长期推断。B-MPES即使适用于研究的2年DBLs,也能产生合理的预测,而mcm更依赖于长期数据来估计平台期,因此从3年开始表现更好。一般来说,LRM外推的可靠性低于替代FPMs和经过验证的SPMs,但仍优于未经验证的SPMs。我们的工作证明了使用包含外部数据源的先进参数模型的潜在好处,例如B-MPES和mcm,可以在有限的随访下从试验数据中准确评估治疗的临床和成本效益。亮点:灵活的先进参数化建模方法可以从早期临床试验数据中为卫生技术评估中的免疫肿瘤学成本效益提供改进的生存推断,从而更好地预测延长的随访。优点包括利用额外的可观察试验数据,外部数据的系统集成,以及对底层过程进行更详细的建模。贝叶斯多参数证据合成在外部数据匹配良好的情况下表现特别好。混合固化模型也表现良好,但根据具体情况,可能需要相对较长的随访时间来确定出现的平台期。在这种情况下,里程碑式反应模型提供了边际效益,可能需要在每个反应组中增加更多的数据和/或增加随访,以支持在每个子组中改进的外推。
{"title":"Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.","authors":"M A Chaudhary,&nbsp;M Edmondson-Jones,&nbsp;G Baio,&nbsp;E Mackay,&nbsp;J R Penrod,&nbsp;D J Sharpe,&nbsp;G Yates,&nbsp;S Rafiq,&nbsp;K Johannesen,&nbsp;M K Siddiqui,&nbsp;J Vanderpuye-Orgle,&nbsp;A Briggs","doi":"10.1177/0272989X221132257","DOIUrl":"https://doi.org/10.1177/0272989X221132257","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;Immuno-oncology (IO) therapies are often associated with delayed responses that are deep and durable, manifesting as long-term survival benefits in patients with metastatic cancer. Complex hazard functions arising from IO treatments may limit the accuracy of extrapolations from standard parametric models (SPMs). We evaluated the ability of flexible parametric models (FPMs) to improve survival extrapolations using data from 2 trials involving patients with non-small-cell lung cancer (NSCLC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Our analyses used consecutive database locks (DBLs) at 2-, 3-, and 5-y minimum follow-up from trials evaluating nivolumab versus docetaxel in patients with pretreated metastatic squamous (CheckMate-017) and nonsquamous (CheckMate-057) NSCLC. For each DBL, SPMs, as well as 3 FPMs-landmark response models (LRMs), mixture cure models (MCMs), and Bayesian multiparameter evidence synthesis (B-MPES)-were estimated on nivolumab overall survival (OS). The performance of each parametric model was assessed by comparing milestone restricted mean survival times (RMSTs) and survival probabilities with results obtained from externally validated SPMs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;For the 2- and 3-y DBLs of both trials, all models tended to underestimate 5-y OS. Predictions from nonvalidated SPMs fitted to the 2-y DBLs were highly unreliable, whereas extrapolations from FPMs were much more consistent between models fitted to successive DBLs. For CheckMate-017, in which an apparent survival plateau emerges in the 3-y DBL, MCMs fitted to this DBL estimated 5-y OS most accurately (11.6% v. 12.3% observed), and long-term predictions were similar to those from the 5-y validated SPM (20-y RMST: 30.2 v. 30.5 mo). For CheckMate-057, where there is no clear evidence of a survival plateau in the early DBLs, only B-MPES was able to accurately predict 5-y OS (14.1% v. 14.0% observed [3-y DBL]).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;We demonstrate that the use of FPMs for modeling OS in NSCLC patients from early follow-up data can yield accurate estimates for RMST observed with longer follow-up and provide similar long-term extrapolations to externally validated SPMs based on later data cuts. B-MPES generated reasonable predictions even when fitted to the 2-y DBLs of the studies, whereas MCMs were more reliant on longer-term data to estimate a plateau and therefore performed better from 3 y. Generally, LRM extrapolations were less reliable than those from alternative FPMs and validated SPMs but remained superior to nonvalidated SPMs. Our work demonstrates the potential benefits of using advanced parametric models that incorporate external data sources, such as B-MPES and MCMs, to allow for accurate evaluation of treatment clinical and cost-effectiveness from trial data with limited follow-up.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Flexible advanced parametric modeling methods can provide improved survival extrapolations for immu","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"91-109"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10350861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Multicriteria Decision-Making Methods for Optimal Treatment Selection in Network Meta-Analysis. 网络元分析中最优治疗选择的多准则决策方法。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221126678
Ioannis Bellos

Background: Network meta-analysis exploits randomized data to compare multiple interventions and generate rankings. Selecting an optimal treatment may be complicated when multiple conflicting outcomes are evaluated in parallel.

Design: The present study suggested the incorporation of multicriteria decision-making methods in network meta-analyses to select the best intervention when multiple outcomes are of interest by creating partial and absolute rankings with the TOPSIS, VIKOR, and PROMETHEE algorithms. The TOPSIS and VIKOR techniques represent distance-based methods for compromise intervention selection, whereas the PROMETHEE analysis method allows the definition of preference and indifference thresholds. In addition, the PROMETHEE technique allows a variety of modeling options by selecting alternative preference functions. Different weights may be applied to outcomes objectively with the entropy method as well as subjectively with the analytic hierarchy process, enabling the individualization of treatment choice depending on the clinical scenario.

Results: Visualization of decision analysis may be performed with multicriteria score-adjusted scatterplots, while league tables may be constructed to depict the PROMETHEE I partial ordering of interventions. A simulated study was performed assuming equal weights of outcomes, and the TOPSIS, VIKOR, and PROMETHEE II methods were compared using a similarity coefficient, indicating a high degree of agreement among methods, especially with higher numbers of interventions.

Conclusions: Multicriteria decision analysis provides a flexible and computationally direct way of selecting compromise interventions and visualizing treatment selection in network meta-analyses. Further research should provide empirical data about the implementation of multicriteria decision analysis in real-world network meta-analyses aiming to define the most suitable method depending on the clinical question.

Highlights: Multicriteria decision-making methods can be implemented in network meta-analysis to indicate compromise interventions.The TOPSIS, VIKOR, and PROMETHEE methods can be used for optimal treatment selection when conflicting outcomes are evaluated.The weights of outcomes can be defined objectively or subjectively, reflecting the priorities of the decision maker.

背景:网络荟萃分析利用随机数据来比较多种干预措施并产生排名。当多个相互冲突的结果并行评估时,选择最佳治疗可能会很复杂。设计:本研究建议在网络荟萃分析中结合多标准决策方法,通过使用TOPSIS、VIKOR和PROMETHEE算法创建部分和绝对排名,在多个结果感兴趣时选择最佳干预措施。TOPSIS和VIKOR技术代表了基于距离的折衷干预选择方法,而PROMETHEE分析方法允许定义偏好和无差异阈值。此外,PROMETHEE技术允许通过选择可选的偏好函数来实现多种建模选项。可以用熵值法客观地对结果施加不同的权重,也可以用层次分析法主观地对结果施加不同的权重,从而根据临床情况实现治疗选择的个性化。结果:决策分析的可视化可以通过多标准分数调整散点图进行,而排位表可以构建来描述干预措施的PROMETHEE I偏序。假设结果的权重相等,进行模拟研究,并使用相似系数比较TOPSIS、VIKOR和PROMETHEE II方法,表明方法之间的一致性很高,特别是在干预数量较多的情况下。结论:在网络荟萃分析中,多标准决策分析为选择折衷干预措施和可视化治疗选择提供了一种灵活且计算直接的方法。进一步的研究应该提供关于在现实世界网络荟萃分析中实施多标准决策分析的经验数据,旨在根据临床问题确定最合适的方法。重点:多标准决策方法可以在网络荟萃分析中实施,以表明折衷干预措施。TOPSIS, VIKOR和PROMETHEE方法可用于评估冲突结果时的最佳治疗选择。结果的权重可以客观地或主观地定义,反映了决策者的优先级。
{"title":"Multicriteria Decision-Making Methods for Optimal Treatment Selection in Network Meta-Analysis.","authors":"Ioannis Bellos","doi":"10.1177/0272989X221126678","DOIUrl":"https://doi.org/10.1177/0272989X221126678","url":null,"abstract":"<p><strong>Background: </strong>Network meta-analysis exploits randomized data to compare multiple interventions and generate rankings. Selecting an optimal treatment may be complicated when multiple conflicting outcomes are evaluated in parallel.</p><p><strong>Design: </strong>The present study suggested the incorporation of multicriteria decision-making methods in network meta-analyses to select the best intervention when multiple outcomes are of interest by creating partial and absolute rankings with the TOPSIS, VIKOR, and PROMETHEE algorithms. The TOPSIS and VIKOR techniques represent distance-based methods for compromise intervention selection, whereas the PROMETHEE analysis method allows the definition of preference and indifference thresholds. In addition, the PROMETHEE technique allows a variety of modeling options by selecting alternative preference functions. Different weights may be applied to outcomes objectively with the entropy method as well as subjectively with the analytic hierarchy process, enabling the individualization of treatment choice depending on the clinical scenario.</p><p><strong>Results: </strong>Visualization of decision analysis may be performed with multicriteria score-adjusted scatterplots, while league tables may be constructed to depict the PROMETHEE I partial ordering of interventions. A simulated study was performed assuming equal weights of outcomes, and the TOPSIS, VIKOR, and PROMETHEE II methods were compared using a similarity coefficient, indicating a high degree of agreement among methods, especially with higher numbers of interventions.</p><p><strong>Conclusions: </strong>Multicriteria decision analysis provides a flexible and computationally direct way of selecting compromise interventions and visualizing treatment selection in network meta-analyses. Further research should provide empirical data about the implementation of multicriteria decision analysis in real-world network meta-analyses aiming to define the most suitable method depending on the clinical question.</p><p><strong>Highlights: </strong>Multicriteria decision-making methods can be implemented in network meta-analysis to indicate compromise interventions.The TOPSIS, VIKOR, and PROMETHEE methods can be used for optimal treatment selection when conflicting outcomes are evaluated.The weights of outcomes can be defined objectively or subjectively, reflecting the priorities of the decision maker.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"78-90"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10354038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Validating the Assumptions of Population Adjustment: Application of Multilevel Network Meta-regression to a Network of Treatments for Plaque Psoriasis. 验证人口调整的假设:将多层次网络元回归应用于斑块状银屑病治疗网络。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 Epub Date: 2022-08-23 DOI: 10.1177/0272989X221117162
David M Phillippo, Sofia Dias, A E Ades, Mark Belger, Alan Brnabic, Daniel Saure, Yves Schymura, Nicky J Welton
<p><strong>Background: </strong>Network meta-analysis (NMA) and indirect comparisons combine aggregate data (AgD) from multiple studies on treatments of interest but may give biased estimates if study populations differ. Population adjustment methods such as multilevel network meta-regression (ML-NMR) aim to reduce bias by adjusting for differences in study populations using individual patient data (IPD) from 1 or more studies under the conditional constancy assumption. A shared effect modifier assumption may also be necessary for identifiability. This article aims to demonstrate how the assumptions made by ML-NMR can be assessed in practice to obtain reliable treatment effect estimates in a target population.</p><p><strong>Methods: </strong>We apply ML-NMR to a network of evidence on treatments for plaque psoriasis with a mix of IPD and AgD trials reporting ordered categorical outcomes. Relative treatment effects are estimated for each trial population and for 3 external target populations represented by a registry and 2 cohort studies. We examine residual heterogeneity and inconsistency and relax the shared effect modifier assumption for each covariate in turn.</p><p><strong>Results: </strong>Estimated population-average treatment effects were similar across study populations, as differences in the distributions of effect modifiers were small. Better fit was achieved with ML-NMR than with NMA, and uncertainty was reduced by explaining within- and between-study variation. We found little evidence that the conditional constancy or shared effect modifier assumptions were invalid.</p><p><strong>Conclusions: </strong>ML-NMR extends the NMA framework and addresses issues with previous population adjustment approaches. It coherently synthesizes evidence from IPD and AgD studies in networks of any size while avoiding aggregation bias and noncollapsibility bias, allows for key assumptions to be assessed or relaxed, and can produce estimates relevant to a target population for decision-making.</p><p><strong>Highlights: </strong>Multilevel network meta-regression (ML-NMR) extends the network meta-analysis framework to synthesize evidence from networks of studies providing individual patient data or aggregate data while adjusting for differences in effect modifiers between studies (population adjustment). We apply ML-NMR to a network of treatments for plaque psoriasis with ordered categorical outcomes.We demonstrate for the first time how ML-NMR allows key assumptions to be assessed. We check for violations of conditional constancy of relative effects (such as unobserved effect modifiers) through residual heterogeneity and inconsistency and the shared effect modifier assumption by relaxing this for each covariate in turn.Crucially for decision making, population-adjusted treatment effects can be produced in any relevant target population. We produce population-average estimates for 3 external target populations, represented by the PsoBest registry and the
背景:网络荟萃分析(NMA)和间接比较结合了多项研究中有关治疗方法的总体数据(AgD),但如果研究人群不同,则可能会得出有偏差的估计值。多层次网络荟萃回归(ML-NMR)等人群调整方法旨在通过在条件恒定假设下使用来自一项或多项研究的患者个体数据(IPD)来调整研究人群的差异,从而减少偏差。共享效应修饰符假设可能也是可识别性的必要条件。本文旨在展示如何在实践中评估 ML-NMR 所做的假设,以便在目标人群中获得可靠的治疗效果估计值:我们将 ML-NMR 应用于斑块状银屑病治疗方法的证据网络,该网络由报告有序分类结果的 IPD 和 AgD 试验组成。我们估算了每个试验人群以及由一项登记和两项队列研究代表的 3 个外部目标人群的相对治疗效果。我们检查了残余异质性和不一致性,并依次放宽了每个协变量的共享效应修饰假定:结果:由于效应修饰因子的分布差异较小,不同研究人群的估计人群平均治疗效果相似。与 NMA 相比,ML-NMR 的拟合效果更好,而且通过解释研究内部和研究之间的差异减少了不确定性。我们发现几乎没有证据表明条件恒定或共享效应修饰因子假设是无效的:结论:ML-NMR 扩展了 NMA 框架,解决了以往人群调整方法存在的问题。它能在任何规模的网络中连贯地综合 IPD 和 AgD 研究的证据,同时避免聚集偏倚和非可比性偏倚,允许对关键假设进行评估或放宽,并能产生与目标人群相关的估计值,以供决策之用:多层次网络荟萃回归(ML-NMR)扩展了网络荟萃分析框架,可从提供单个患者数据或总体数据的研究网络中综合证据,同时调整不同研究之间效应修饰因子的差异(群体调整)。我们首次展示了 ML-NMR 如何评估关键假设。我们通过残余异质性和不一致性检查相对效应条件恒定性的违反情况(如未观察到的效应修饰因子),并通过依次放宽每个协变量的共享效应修饰因子假设检查违反情况。我们得出了 3 个外部目标人群的人群平均估计值,分别以 PsoBest 登记、PROSPECT 和 Chiricozzi 2019 队列研究为代表。
{"title":"Validating the Assumptions of Population Adjustment: Application of Multilevel Network Meta-regression to a Network of Treatments for Plaque Psoriasis.","authors":"David M Phillippo, Sofia Dias, A E Ades, Mark Belger, Alan Brnabic, Daniel Saure, Yves Schymura, Nicky J Welton","doi":"10.1177/0272989X221117162","DOIUrl":"10.1177/0272989X221117162","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Network meta-analysis (NMA) and indirect comparisons combine aggregate data (AgD) from multiple studies on treatments of interest but may give biased estimates if study populations differ. Population adjustment methods such as multilevel network meta-regression (ML-NMR) aim to reduce bias by adjusting for differences in study populations using individual patient data (IPD) from 1 or more studies under the conditional constancy assumption. A shared effect modifier assumption may also be necessary for identifiability. This article aims to demonstrate how the assumptions made by ML-NMR can be assessed in practice to obtain reliable treatment effect estimates in a target population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We apply ML-NMR to a network of evidence on treatments for plaque psoriasis with a mix of IPD and AgD trials reporting ordered categorical outcomes. Relative treatment effects are estimated for each trial population and for 3 external target populations represented by a registry and 2 cohort studies. We examine residual heterogeneity and inconsistency and relax the shared effect modifier assumption for each covariate in turn.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Estimated population-average treatment effects were similar across study populations, as differences in the distributions of effect modifiers were small. Better fit was achieved with ML-NMR than with NMA, and uncertainty was reduced by explaining within- and between-study variation. We found little evidence that the conditional constancy or shared effect modifier assumptions were invalid.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;ML-NMR extends the NMA framework and addresses issues with previous population adjustment approaches. It coherently synthesizes evidence from IPD and AgD studies in networks of any size while avoiding aggregation bias and noncollapsibility bias, allows for key assumptions to be assessed or relaxed, and can produce estimates relevant to a target population for decision-making.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Multilevel network meta-regression (ML-NMR) extends the network meta-analysis framework to synthesize evidence from networks of studies providing individual patient data or aggregate data while adjusting for differences in effect modifiers between studies (population adjustment). We apply ML-NMR to a network of treatments for plaque psoriasis with ordered categorical outcomes.We demonstrate for the first time how ML-NMR allows key assumptions to be assessed. We check for violations of conditional constancy of relative effects (such as unobserved effect modifiers) through residual heterogeneity and inconsistency and the shared effect modifier assumption by relaxing this for each covariate in turn.Crucially for decision making, population-adjusted treatment effects can be produced in any relevant target population. We produce population-average estimates for 3 external target populations, represented by the PsoBest registry and the ","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"53-67"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10697827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. R语言中队列状态转换模型的入门教程,使用成本效益分析示例。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221103163
Fernando Alarid-Escudero, Eline Krijkamp, Eva A Enns, Alan Yang, M G Myriam Hunink, Petros Pechlivanoglou, Hawre Jalal

Decision models can combine information from different sources to simulate the long-term consequences of alternative strategies in the presence of uncertainty. A cohort state-transition model (cSTM) is a decision model commonly used in medical decision making to simulate the transitions of a hypothetical cohort among various health states over time. This tutorial focuses on time-independent cSTM, in which transition probabilities among health states remain constant over time. We implement time-independent cSTM in R, an open-source mathematical and statistical programming language. We illustrate time-independent cSTMs using a previously published decision model, calculate costs and effectiveness outcomes, and conduct a cost-effectiveness analysis of multiple strategies, including a probabilistic sensitivity analysis. We provide open-source code in R to facilitate wider adoption. In a second, more advanced tutorial, we illustrate time-dependent cSTMs.

决策模型可以结合来自不同来源的信息来模拟存在不确定性的备选策略的长期后果。队列状态转移模型(cohort state-transition model, cSTM)是医学决策中常用的一种决策模型,用于模拟假设队列在不同健康状态下随时间的转变。本教程重点介绍与时间无关的cSTM,其中运行状态之间的转换概率随时间保持不变。我们在R中实现了与时间无关的cSTM, R是一种开源的数学和统计编程语言。我们使用先前发布的决策模型说明了时间无关的cstm,计算了成本和有效性结果,并对多种策略进行了成本效益分析,包括概率敏感性分析。我们提供了R语言的开源代码,以促进更广泛的采用。在第二篇更高级的教程中,我们将演示与时间相关的cstm。
{"title":"An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example.","authors":"Fernando Alarid-Escudero,&nbsp;Eline Krijkamp,&nbsp;Eva A Enns,&nbsp;Alan Yang,&nbsp;M G Myriam Hunink,&nbsp;Petros Pechlivanoglou,&nbsp;Hawre Jalal","doi":"10.1177/0272989X221103163","DOIUrl":"https://doi.org/10.1177/0272989X221103163","url":null,"abstract":"<p><p>Decision models can combine information from different sources to simulate the long-term consequences of alternative strategies in the presence of uncertainty. A cohort state-transition model (cSTM) is a decision model commonly used in medical decision making to simulate the transitions of a hypothetical cohort among various health states over time. This tutorial focuses on time-independent cSTM, in which transition probabilities among health states remain constant over time. We implement time-independent cSTM in R, an open-source mathematical and statistical programming language. We illustrate time-independent cSTMs using a previously published decision model, calculate costs and effectiveness outcomes, and conduct a cost-effectiveness analysis of multiple strategies, including a probabilistic sensitivity analysis. We provide open-source code in R to facilitate wider adoption. In a second, more advanced tutorial, we illustrate time-dependent cSTMs.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"3-20"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742144/pdf/nihms-1806797.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9703316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Dynamics of Respiratory Infectious Diseases in Incarcerated and Free-Living Populations: A Simulation Modeling Study. 被监禁和自由生活人群中呼吸道传染病的动态变化:模拟模型研究。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 Epub Date: 2022-07-29 DOI: 10.1177/0272989X221115364
Christopher Weyant, Serin Lee, Jason R Andrews, Fernando Alarid-Escudero, Jeremy D Goldhaber-Fiebert
<p><strong>Background: </strong>Historically, correctional facilities have had large outbreaks of respiratory infectious diseases like COVID-19. Hence, importation and exportation of such diseases from correctional facilities raises substantial concern.</p><p><strong>Methods: </strong>We developed a stochastic simulation model of transmission of respiratory infectious diseases within and between correctional facilities and the community. We investigated the infection dynamics, key governing factors, and relative importance of different infection routes (e.g., incarcerations and releases versus correctional staff). We also developed machine-learning meta-models of the simulation model, which allowed us to examine how our findings depended on different disease, correctional facility, and community characteristics.</p><p><strong>Results: </strong>We find a magnification-reflection dynamic: a small outbreak in the community can cause a larger outbreak in the correction facility, which can then cause a second, larger outbreak in the community. This dynamic is strongest when community size is relatively small as compared with the size of the correctional population, the initial community R-effective is near 1, and initial prevalence of immunity in the correctional population is low. The timing of the correctional magnification and community reflection peaks in infection prevalence are primarily governed by the initial R-effective for each setting. Because the release rates from prisons are low, our model suggests correctional staff may be a more important infection entry route into prisons than incarcerations and releases; in jails, where incarceration and release rates are much higher, our model suggests the opposite.</p><p><strong>Conclusions: </strong>We find that across many combinations of respiratory pathogens, correctional settings, and communities, there can be substantial magnification-reflection dynamics, which are governed by several key factors. Our goal was to derive theoretical insights relevant to many contexts; our findings should be interpreted accordingly.</p><p><strong>Highlights: </strong>We find a magnification-reflection dynamic: a small outbreak in a community can cause a larger outbreak in a correctional facility, which can then cause a second, larger outbreak in the community.For public health decision makers considering contexts most susceptible to this dynamic, we find that the dynamic is strongest when the community size is relatively small, initial community R-effective is near 1, and the initial prevalence of immunity in the correctional population is low; the timing of the correctional magnification and community reflection peaks in infection prevalence are primarily governed by the initial R-effective for each setting.We find that correctional staff may be a more important infection entry route into prisons than incarcerations and releases; however, for jails, the relative importance of the entry routes may be reversed.F
背景:历史上,惩教机构曾大规模爆发过 COVID-19 等呼吸道传染病。因此,此类疾病从惩教机构的输入和输出引起了人们的极大关注:我们建立了一个呼吸道传染病在惩教机构内部以及惩教机构与社区之间传播的随机模拟模型。我们研究了感染动态、关键影响因素以及不同感染途径(如监禁和释放与管教人员)的相对重要性。我们还开发了模拟模型的机器学习元模型,这使我们能够研究我们的发现如何取决于不同的疾病、惩教机构和社区特征:我们发现了一种放大-反射动态:社区中的小规模疫情会导致惩教机构中更大规模的疫情爆发,而惩教机构又会导致社区中第二次更大规模的疫情爆发。当社区规模相对于矫正人群规模较小、社区初始 R 效应接近 1 且矫正人群初始免疫流行率较低时,这种态势最为明显。感染率的矫正放大峰和社区反射峰的时间主要取决于每种环境的初始 R-效应。由于监狱的释放率很低,我们的模型表明,与监禁和释放相比,管教人员可能是进入监狱的更重要的感染途径;而在监禁和释放率更高的监狱中,我们的模型表明情况恰恰相反:我们发现,在呼吸道病原体、管教环境和社区的多种组合中,可能存在着大量的放大-反射动态,而这又受几个关键因素的制约。我们的目标是得出与多种情况相关的理论见解;我们的发现也应相应地加以解释:我们发现了一种放大-反射动态:社区中的小规模疫情会导致惩教机构中更大规模的疫情爆发,而惩教机构又会导致社区中第二次更大规模的疫情爆发。对于考虑最易受这种动态影响的环境的公共卫生决策者来说,我们发现,当社区规模相对较小、社区初始 R 效应接近 1,以及矫治人群的初始免疫流行率较低时,这种动态影响最大;矫治放大和社区反射感染流行高峰的时间主要受每种环境的初始 R 效应的影响。我们发现,与监禁和释放相比,管教人员可能是进入监狱的更重要的感染途径;然而,对于监狱来说,进入途径的相对重要性可能正好相反。对于建模者来说,我们将模拟建模、机器学习元建模和可解释的机器学习结合起来,以检验我们的发现如何依赖于不同的疾病、管教设施和社区特征;我们发现这些发现总体上是稳健的。
{"title":"Dynamics of Respiratory Infectious Diseases in Incarcerated and Free-Living Populations: A Simulation Modeling Study.","authors":"Christopher Weyant, Serin Lee, Jason R Andrews, Fernando Alarid-Escudero, Jeremy D Goldhaber-Fiebert","doi":"10.1177/0272989X221115364","DOIUrl":"10.1177/0272989X221115364","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Historically, correctional facilities have had large outbreaks of respiratory infectious diseases like COVID-19. Hence, importation and exportation of such diseases from correctional facilities raises substantial concern.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We developed a stochastic simulation model of transmission of respiratory infectious diseases within and between correctional facilities and the community. We investigated the infection dynamics, key governing factors, and relative importance of different infection routes (e.g., incarcerations and releases versus correctional staff). We also developed machine-learning meta-models of the simulation model, which allowed us to examine how our findings depended on different disease, correctional facility, and community characteristics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We find a magnification-reflection dynamic: a small outbreak in the community can cause a larger outbreak in the correction facility, which can then cause a second, larger outbreak in the community. This dynamic is strongest when community size is relatively small as compared with the size of the correctional population, the initial community R-effective is near 1, and initial prevalence of immunity in the correctional population is low. The timing of the correctional magnification and community reflection peaks in infection prevalence are primarily governed by the initial R-effective for each setting. Because the release rates from prisons are low, our model suggests correctional staff may be a more important infection entry route into prisons than incarcerations and releases; in jails, where incarceration and release rates are much higher, our model suggests the opposite.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;We find that across many combinations of respiratory pathogens, correctional settings, and communities, there can be substantial magnification-reflection dynamics, which are governed by several key factors. Our goal was to derive theoretical insights relevant to many contexts; our findings should be interpreted accordingly.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;We find a magnification-reflection dynamic: a small outbreak in a community can cause a larger outbreak in a correctional facility, which can then cause a second, larger outbreak in the community.For public health decision makers considering contexts most susceptible to this dynamic, we find that the dynamic is strongest when the community size is relatively small, initial community R-effective is near 1, and the initial prevalence of immunity in the correctional population is low; the timing of the correctional magnification and community reflection peaks in infection prevalence are primarily governed by the initial R-effective for each setting.We find that correctional staff may be a more important infection entry route into prisons than incarcerations and releases; however, for jails, the relative importance of the entry routes may be reversed.F","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"42-52"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742162/pdf/nihms-1822488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10459855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. R语言中时间依赖的队列状态转移模型教程,使用成本效益分析示例。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.1177/0272989X221121747
Fernando Alarid-Escudero, Eline Krijkamp, Eva A Enns, Alan Yang, M G Myriam Hunink, Petros Pechlivanoglou, Hawre Jalal

In an introductory tutorial, we illustrated building cohort state-transition models (cSTMs) in R, where the state transition probabilities were constant over time. However, in practice, many cSTMs require transitions, rewards, or both to vary over time (time dependent). This tutorial illustrates adding 2 types of time dependence using a previously published cost-effectiveness analysis of multiple strategies as an example. The first is simulation-time dependence, which allows for the transition probabilities to vary as a function of time as measured since the start of the simulation (e.g., varying probability of death as the cohort ages). The second is state-residence time dependence, allowing for history by tracking the time spent in any particular health state using tunnel states. We use these time-dependent cSTMs to conduct cost-effectiveness and probabilistic sensitivity analyses. We also obtain various epidemiological outcomes of interest from the outputs generated from the cSTM, such as survival probability and disease prevalence, often used for model calibration and validation. We present the mathematical notation first, followed by the R code to execute the calculations. The full R code is provided in a public code repository for broader implementation.

在介绍性教程中,我们说明了在R中构建队列状态转移模型(cstm),其中状态转移概率随时间不变。然而,在实践中,许多cstm要求转换、奖励或两者都随时间变化(时间依赖)。本教程以先前发布的多种策略的成本效益分析为例,说明了添加两种类型的时间依赖性。第一个是模拟时间依赖性,它允许过渡概率作为模拟开始以来测量的时间的函数而变化(例如,随着队列年龄的变化而变化的死亡概率)。第二种是状态驻留时间依赖,通过使用隧道状态跟踪在任何特定健康状态下花费的时间来实现历史记录。我们使用这些时间相关的cstm进行成本效益和概率敏感性分析。我们还从cSTM产生的输出中获得各种感兴趣的流行病学结果,例如生存率和患病率,通常用于模型校准和验证。我们首先给出数学符号,然后是执行计算的R代码。完整的R代码在公共代码存储库中提供,用于更广泛的实现。
{"title":"A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example.","authors":"Fernando Alarid-Escudero,&nbsp;Eline Krijkamp,&nbsp;Eva A Enns,&nbsp;Alan Yang,&nbsp;M G Myriam Hunink,&nbsp;Petros Pechlivanoglou,&nbsp;Hawre Jalal","doi":"10.1177/0272989X221121747","DOIUrl":"https://doi.org/10.1177/0272989X221121747","url":null,"abstract":"<p><p>In an introductory tutorial, we illustrated building cohort state-transition models (cSTMs) in R, where the state transition probabilities were constant over time. However, in practice, many cSTMs require transitions, rewards, or both to vary over time (time dependent). This tutorial illustrates adding 2 types of time dependence using a previously published cost-effectiveness analysis of multiple strategies as an example. The first is simulation-time dependence, which allows for the transition probabilities to vary as a function of time as measured since the start of the simulation (e.g., varying probability of death as the cohort ages). The second is state-residence time dependence, allowing for history by tracking the time spent in any particular health state using tunnel states. We use these time-dependent cSTMs to conduct cost-effectiveness and probabilistic sensitivity analyses. We also obtain various epidemiological outcomes of interest from the outputs generated from the cSTM, such as survival probability and disease prevalence, often used for model calibration and validation. We present the mathematical notation first, followed by the R code to execute the calculations. The full R code is provided in a public code repository for broader implementation.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":"43 1","pages":"21-41"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844995/pdf/nihms-1829740.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10536012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
Medical Decision Making
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1